# lung adenocarcinoma (LUAD) - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 2
- Task type: PROGNOSIS
- Tissue / sample source: lung adenocarcinoma tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: a2c9355177479f23c6c81afe1b39ba697ac131cc344bb83120b98e2c6bbfee49
- Response HTTP status: 200
- Prompt tokens: 14427
- Completion tokens: 7887
- Reasoning tokens: 4660
- Total tokens: 22314
- API requests reported: 1
- Elapsed seconds: 156.888
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 957.651
- Question handoff seconds: 970.897
- Final benchmark system: E2seq; file rank 2/5; original repeat 2; model vendor: OpenAI

---
**Data-Quality Warning**
The direct survival statistics are technically suspicious: many genes have HR = `5.1847055e+21` or HR near zero with `P = 0` and `FDR = 0`, which is consistent with numerical underflow, complete separation, very sparse expression, or model instability rather than biologically interpretable effect sizes. I therefore treat the **direction** of association as usable exploratory evidence, but not the absolute HR magnitude for the saturated features. External statistical validation was not performed.

**Overall Interpretation**
The most defensible interpretation is that worse OS in this LUAD tumor dataset is associated with a mixed transcriptomic pattern of **developmental/Wnt-related plasticity**, **cell adhesion–migration/cytoskeletal remodeling**, **cell-surface glycosylation**, and a prominent **noncoding/pseudogene/sex-linked transcript signature**. The protein-coding, biologically interpretable risk genes include `DKK1`, `TLE1`, `PITX3`, `VAX1`, `ITGB1-DT`, `KRT6A`, `FUT4`, `RHOF`, `LDLRAD3`, and `RGS20`. In contrast, many of the strongest numerical HRs are from lncRNAs, pseudogenes, Y-linked/testis-associated genes, or small RNA features, so those should be treated primarily as **candidate biomarkers or confounding signals**, not as established mechanisms.

## Core Biological Programs

| Program | Prognostic association | Supporting genes | Standardized pathway / ontology | Interpretation | Evidence strength and limitations |
|---|---:|---|---|---|---|
| **Developmental / Wnt signaling and epithelial plasticity** | Risk-associated | `DKK1` HR 1.475, `TLE1` HR 1.484, `PITX3` HR 1.429, `VAX1` HR 1.335, `LDLRAD3` HR 1.420 | GO: regulation of Wnt signaling pathway; KEGG: Wnt signaling pathway; planar cell polarity pathway | Multiple risk genes converge on developmental transcriptional control and Wnt/PCP-related biology. In LUAD, this plausibly reflects dedifferentiation, invasive plasticity, or altered tumor–stromal signaling rather than a single linear pathway. | **Supported hypothesis.** Direct dataset evidence is strong for association, and pathway/ontology evidence supports plausibility. Limitation: no formal enrichment statistic or independent LUAD OS replication was supplied; `DKK1` can contextually inhibit or modulate Wnt rather than simply activate it. |
| **Adhesion, migration, cytoskeletal remodeling, and junction disruption** | Risk-associated | `ITGB1-DT` HR 1.302, `RHOF` HR 1.403, `KRT6A` HR 1.390, `FUT4` HR 1.403, `LDLRAD3` HR 1.420 | GO: cell junction disassembly; GO terms for actin filament organization/cell migration for `RHOF`; pathway/network evidence from STRING/QuickGO | These genes point to altered epithelial structure, motility, integrin-associated signaling, and cytoskeletal regulation, all compatible with more aggressive LUAD behavior. | **Supported hypothesis.** Direct survival associations are consistent across several genes. External support includes `RHOF` GO annotations for actin/cell migration and STRING functional links, plus LUAD-related ITGB1-DT literature. Limitations: tissue composition, basal/squamous-like contamination, or stromal admixture could produce similar signals. |
| **Cell-surface glycosylation and membrane remodeling** | Mostly risk-associated, with one protective-associated signal | `FUT4` HR 1.403 risk, `KRT6A` HR 1.390 risk, `RHCG` HR 1.290 risk, `CMAHP` HR 0.706 protective | KEGG: mannose type O-glycan biosynthesis; KEGG: glycosphingolipid biosynthesis | The glycosylation-related signal suggests changes in cell-surface identity, adhesion, immune recognition, or metastatic niche biology. `FUT4` is the clearest risk-associated anchor; `CMAHP` being protective makes the program direction partly mixed. | **Exploratory-to-supported hypothesis.** Pathway recurrence supports plausibility, but the program is driven by few interpretable genes and includes pseudogene/annotation complexity. It should not be called enriched or therapeutically actionable without formal enrichment and functional validation. |
| **G-protein / small GTPase signaling** | Risk-associated | `RGS20` HR 1.352, `RHOF` HR 1.403 | Reactome: G alpha (i/z) signaling events for `RGS20`; QuickGO: GTPase activity, GTPase activator activity; `RHOF` small GTPase/cytoskeleton annotations | This program links receptor-proximal signaling to migration and cytoskeletal remodeling. `RGS20` regulates G-protein signaling, while `RHOF` connects small GTPase biology to actin organization. | **Exploratory hypothesis.** Direct dataset evidence supports risk association, and ontology/network records support biological plausibility. Limitation: this is a small module, and STRING relationships are functional/network evidence unless independently shown to be direct physical interactions. |
| **Noncoding, pseudogene, Y-linked/testis-associated transcript signature** | Predominantly risk-associated; a few protective features | Risk: `RBMY1F`, `FAM9A`, `RBMY2AP`, `TTTY4C`, `USP9YP3`, `TEX13A`, `MIR509-1`, many `RP11/CTD/LINC` features; protective: `TCP10L3`, `RBMXP1`, `CRNDE`, `CMAHP` | No single robust canonical pathway; expression/tissue and genetic annotation records exist for many selected genes | The cohort is numerically dominated by ncRNA/pseudogene/sex-linked features with extreme HRs. This could reflect cancer-testis activation, sex composition, low-expression separation, mapping artifacts, or real noncoding prognostic biology. | **Exploratory / high-risk for confounding.** Direct association is strong in the uploaded table, but effect sizes are not credible as magnitudes. `Y_RNA` has direction conflict across rows, and many features require raw-count and mapping validation before biological interpretation. |

## Key Genes and Interaction Modules

| Candidate | Current dataset association | Role in programs | Relationship type |
|---|---:|---|---|
| **`DKK1`** | Risk, HR 1.475, FDR 3.547e-07 | Anchor of the Wnt/developmental plasticity program | Pathway/ontology relationship to Wnt signaling; not a direct physical interaction with other selected genes based on supplied evidence. |
| **`TLE1` / `PITX3` / `VAX1` developmental transcription module** | Risk: `TLE1` HR 1.484, `PITX3` HR 1.429, `VAX1` HR 1.335 | Suggests developmental transcriptional reprogramming linked to worse OS | Indirect regulatory/pathway-level relationship; direct interaction among these selected genes was not supplied. |
| **`ITGB1-DT`** | Risk, HR 1.302, FDR 1.478e-04 | Links adhesion/integrin biology with prognosis | Published LUAD bioinformatics/experimental report proposed an `ITGB1-DT/ARNTL2` biomarker axis, but `ARNTL2` is not selected in this dataset; relationship is regulatory/biomarker-level, not direct physical interaction (PMID:34906142). |
| **`RHOF`** | Risk, HR 1.403, FDR 3.997e-04 | Small GTPase/cytoskeletal migration signal | QuickGO supports actin organization, cell migration, and small GTPase signaling; STRING links to `ACTN1` and `ARHGAP1` are network/functional associations, not automatically direct physical interactions. |
| **`RGS20`** | Risk, HR 1.352, FDR 5.793e-04 | G-protein signaling module | Reactome supports G alpha signaling; STRING links to `GNAZ`, `GNB5`, `GNAI2`, and `GNAQ` are functional/network interactions unless experimentally specified as physical. |
| **`FUT4`** | Risk, HR 1.403, FDR 2.935e-04 | Cell-surface glycosylation and adhesion biology | KEGG glycosylation pathway co-membership; STRING links to glycosylation genes such as `B3GNT3`/`B4GALT1` are pathway/network associations, not direct physical interactions. |
| **`KRT6A`** | Risk, HR 1.390, FDR 2.784e-04 | Epithelial stress/basal-like or injury-response phenotype | Mostly expression/ontology contextual evidence here; could represent tumor-cell state or epithelial composition rather than causal aggressiveness. |
| **Y-linked/testis-associated cluster** | Strongly risk-associated but saturated: e.g., `RBMY1F`, `FAM9A`, `RBMY2AP`, `TTTY4C`, `USP9YP3`, `TEX13A` | Candidate cancer-testis/sex-linked prognostic signature or confounding signal | Mostly expression/genetic annotation and indirect co-occurrence; no coherent direct interaction module supplied. |
| **miRNA/small RNA features** | Risk: `MIR509-1` HR 1822.599, `MIR3924`, `MIR8065`, `MIR6862-1`; `Y_RNA` direction-conflict | Possible noncoding RNA biomarker signal | Insufficient evidence for mechanism; extreme HRs require raw-count validation and duplicate/probe reconciliation. |
| **Protective-associated set** | `RBMXP1` HR 0.2118, `CRNDE` HR 0.716, `CMAHP` HR 0.706, `TCP10L3` HR 1.929e-22 | Counter-signal to the dominant risk-associated pattern | No coherent shared pathway is sufficiently supported; treat as candidate protective biomarkers, not a mechanistic module. |

## Validation Priorities

| Priority | Class | Why prioritize | Dataset evidence | External evidence | Next validation step | Status |
|---|---|---|---|---|---|---|
| **Reproduce the survival model and resolve saturated HRs** | Confounding or composition check | The top associations are numerically degenerate and may reflect complete separation, sparse expression, or coding/mapping artifacts. | Many HRs are `5.1847055e+21` with `P = 0`, `FDR = 0`; `TCP10L3` is near-zero HR; `Y_RNA` has direction conflict. | No independent cohort statistic supplied. | Inspect raw expression distributions, event counts, censoring, missingness, duplicate probes, and refit penalized/Firth Cox plus multivariable Cox with stage, sex, age, smoking, and batch. | **Exploratory hypothesis** |
| **Test the Wnt/developmental plasticity program** | Mechanistic hypothesis | This is the most coherent interpretable tumor-biology signal among protein-coding genes. | `DKK1`, `TLE1`, `PITX3`, `VAX1`, `LDLRAD3` are risk-associated. | GO/KEGG records support Wnt/PCP and junction-related biology; no independent OS replication statistic supplied. | Validate by multivariable survival modeling, pathway scoring, IHC/RNA in situ for DKK1/TLE1, and perturbation assays in LUAD models. | **Supported hypothesis** |
| **Validate the `ITGB1-DT` adhesion/invasion biomarker axis** | Biomarker | It is directly risk-associated and has LUAD-specific literature support. | `ITGB1-DT` HR 1.302, FDR 1.478e-04. | PMID:34906142 reported an `ITGB1-DT/ARNTL2` LUAD biomarker axis; this supports plausibility but is not cohort replication of the current result. | Test `ITGB1-DT` and `ARNTL2` jointly in an independent LUAD OS cohort and perform knockdown/overexpression assays. | **Supported hypothesis** |
| **Assess glycosylation and cell-surface remodeling** | Mechanistic hypothesis / therapeutic target exploratory | `FUT4` and related surface-state genes may influence adhesion, immune recognition, or metastatic potential. | `FUT4`, `KRT6A`, and `RHCG` are risk-associated; `CMAHP` is protective-associated. | KEGG glycosylation pathway evidence supports plausibility; therapeutic relevance is not established by drug/source presence alone. | Perform glycomic profiling, FUT4 perturbation, immune-cell deconvolution, and test whether glycosylation score predicts OS after covariate adjustment. | **Exploratory hypothesis** |
| **Separate biological signal from sex, tumor purity, and cell-composition confounding** | Confounding or composition check | Y-linked/testis-associated and epithelial-state genes can be driven by sex imbalance, tumor purity, or cell mixture. | Dominant risk signal includes Y-linked/testis/pseudogene features plus epithelial markers such as `KRT6A`. | Expression/tissue records exist for many genes, but these are contextual and not replication. | Stratify by sex, adjust for purity/stage/smoking/treatment, run tumor microenvironment deconvolution, and confirm with spatial or single-cell data. | **Exploratory hypothesis** |

## Major Limitations and Alternative Explanations

1. **Model instability / complete separation:** saturated HRs and zero P/FDR values mean absolute effect sizes should not be interpreted biologically.
2. **Feature annotation and mapping ambiguity:** many top features are pseudogenes, lncRNAs, small RNAs, Y-linked genes, or unmapped Ensembl IDs; raw-read mappability and duplicate-probe reconciliation are essential.
3. **Clinical and composition confounding:** sex, age, stage, smoking, treatment, tumor purity, stromal content, immune infiltration, and epithelial subtype could explain parts of the survival association.
4. **Pathway recurrence is not formal enrichment:** GO/KEGG/Reactome records provide contextual support, but no new enrichment P value or independent pathway statistic was supplied.
5. **Association is not causation:** the dataset supports prognostic association only; mechanistic claims require perturbation experiments and independent LUAD OS validation.

In short, the most biologically credible signal is a **risk-associated LUAD plasticity/invasion program involving Wnt-developmental signaling, adhesion–migration, cytoskeletal regulation, and surface glycosylation**, but the numerically strongest features require stringent statistical, annotation, and confounding validation before being treated as biological drivers or clinical biomarkers.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=38, external claims checked=0, external mismatches=0, status=passed.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 53/100 selected items (records returned); cbioportal 51/100 selected items (records returned); chembl 16/100 selected items (records returned); civic 1/100 selected items (records returned); clinicaltrials 6/100 selected items (records returned); clinvar 30/100 selected items (records returned); ensembl 11/100 selected items (partially returned; some queries failed); europepmc 362 articles / initial full-cohort RAG 100 queries + 4 current-round queries; some queries failed; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 56/100 selected items (partially returned; some queries failed); intact 18/100 selected items (records returned); mygene 59/100 selected items (records returned); omnipath 3/100 selected items (records returned); opentargets 55/100 selected items (records returned); pubmed 202 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 17/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 17/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 2/100 selected items (records returned); string 14/100 selected items (records returned); trrust 4/100 selected items (records returned)
